Nationwide Fund Advisors cut its stake in NxStage Medical, Inc. (NASDAQ:NXTM) by 84.8% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 34,882 shares of the medical device company’s stock after selling 194,071 shares during the period. Nationwide Fund Advisors owned 0.05% of NxStage Medical worth $963,000 at the end of the most recent reporting period.
Other institutional investors and hedge funds also recently modified their holdings of the company. Longfellow Investment Management Co. LLC bought a new stake in shares of NxStage Medical during the third quarter valued at approximately $373,000. Koch Industries Inc. bought a new stake in NxStage Medical in the 2nd quarter worth approximately $227,000. The Manufacturers Life Insurance Company grew its position in NxStage Medical by 2.1% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 50,336 shares of the medical device company’s stock worth $1,262,000 after purchasing an additional 1,059 shares during the period. Redmile Group LLC bought a new stake in NxStage Medical in the 2nd quarter worth approximately $16,480,000. Finally, State Street Corp grew its position in NxStage Medical by 8.4% in the 2nd quarter. State Street Corp now owns 1,340,810 shares of the medical device company’s stock worth $33,618,000 after purchasing an additional 104,007 shares during the period. Institutional investors and hedge funds own 85.35% of the company’s stock.
A number of equities research analysts have recently issued reports on NXTM shares. Zacks Investment Research downgraded shares of NxStage Medical from a “hold” rating to a “sell” rating in a research report on Tuesday, November 14th. Canaccord Genuity reissued a “hold” rating and set a $30.00 price objective on shares of NxStage Medical in a research report on Tuesday, October 17th. Finally, Northland Securities restated a “hold” rating and set a $30.00 target price on shares of NxStage Medical in a research note on Wednesday, November 8th. One research analyst has rated the stock with a sell rating and nine have assigned a hold rating to the stock. NxStage Medical presently has an average rating of “Hold” and an average price target of $30.25.
In other news, SVP Winifred L. Swan sold 3,500 shares of the business’s stock in a transaction dated Wednesday, December 20th. The shares were sold at an average price of $25.35, for a total value of $88,725.00. Following the sale, the senior vice president now directly owns 14,270 shares in the company, valued at approximately $361,744.50. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Over the last 90 days, insiders sold 10,500 shares of company stock worth $275,030. Insiders own 4.70% of the company’s stock.
Shares of NxStage Medical, Inc. (NXTM) opened at $24.77 on Friday. NxStage Medical, Inc. has a fifty-two week low of $20.45 and a fifty-two week high of $30.80. The firm has a market cap of $1,640.00, a PE ratio of -117.95 and a beta of -0.08.
COPYRIGHT VIOLATION NOTICE: “Nationwide Fund Advisors Lowers Stake in NxStage Medical, Inc. (NXTM)” was first posted by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are reading this report on another website, it was illegally stolen and reposted in violation of US international copyright and trademark laws. The legal version of this report can be viewed at https://ledgergazette.com/2018/01/14/nationwide-fund-advisors-sells-194071-shares-of-nxstage-medical-inc-nxtm.html.
NxStage Medical Company Profile
NxStage Medical, Inc is a medical technology company. The Company develops, manufactures and markets products and services for patients suffering from chronic or acute kidney failure. It operates through three segments. The System One segment includes revenues from the sale and rental of the System One and PureFlow SL dialysate preparation equipment and the sale of disposable products in the home and critical care markets.
Receive News Ratings for NxStage Medical Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for NxStage Medical and related companies with MarketBeat.com’s FREE daily email newsletter.